Clinical Trials Browser

Recruiting × famitinib × Breast × Clear all

NCT05582499 2026-05-28

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06516289 2024-12-12

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Phase 2 Recruiting

BRCA-Mutated Breast Carcinoma

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT05760378 2024-02-06

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Phase 3 Recruiting

Triple Negative Breast Neoplasms